Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review

Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid... BioDrugs (2018) 32:193–199 https://doi.org/10.1007/s40259-018-0283-4 SYSTEMATIC REVIEW Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review 1,2 3 4 5 • • • • Robert J. Moots Cinzia Curiale Danielle Petersel Catherine Rolland 4 6 Heather Jones Eduardo Mysler Published online: 22 May 2018 Springer International Publishing AG, part of Springer Nature 2018 Abstract patients with RA receiving originator biologics and biosimilars Objective Regulatory approval of biosimilar versions of orig- in biosimilar trials than among patients receiving the originator inator biotherapeutics requires that new biological products be biologics in pivotal trials. In etanercept studies in PsO, a dif- highly similar to originator products, with no clinically mean- ference was observed in Psoriasis Area and Severity Index 75% ingful differences in safety, purity, and potency. In some trials response rates between biosimilar and pivotal trials. Insufficient of biosimilars of tumor necrosis factor inhibitors for the treat- efficacy data were available from adalimumab and infliximab ment of rheumatoid arthritis (RA) and plaque psoriasis (PsO), biosimilar studies in PsO to determine any differences in treat- pre-specified margins for efficacy and safety have been met, but ment responses between pivotal and biosimilar studies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png BioDrugs Springer Journals

Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review

Loading next page...
 
/lp/springer_journal/efficacy-and-safety-outcomes-for-originator-tnf-inhibitors-and-OlfYw4m03f
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Biomedicine; Molecular Medicine; Antibodies; Cancer Research; Pharmacotherapy
ISSN
1173-8804
eISSN
1179-190X
D.O.I.
10.1007/s40259-018-0283-4
Publisher site
See Article on Publisher Site

Abstract

BioDrugs (2018) 32:193–199 https://doi.org/10.1007/s40259-018-0283-4 SYSTEMATIC REVIEW Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review 1,2 3 4 5 • • • • Robert J. Moots Cinzia Curiale Danielle Petersel Catherine Rolland 4 6 Heather Jones Eduardo Mysler Published online: 22 May 2018 Springer International Publishing AG, part of Springer Nature 2018 Abstract patients with RA receiving originator biologics and biosimilars Objective Regulatory approval of biosimilar versions of orig- in biosimilar trials than among patients receiving the originator inator biotherapeutics requires that new biological products be biologics in pivotal trials. In etanercept studies in PsO, a dif- highly similar to originator products, with no clinically mean- ference was observed in Psoriasis Area and Severity Index 75% ingful differences in safety, purity, and potency. In some trials response rates between biosimilar and pivotal trials. Insufficient of biosimilars of tumor necrosis factor inhibitors for the treat- efficacy data were available from adalimumab and infliximab ment of rheumatoid arthritis (RA) and plaque psoriasis (PsO), biosimilar studies in PsO to determine any differences in treat- pre-specified margins for efficacy and safety have been met, but ment responses between pivotal and biosimilar studies.

Journal

BioDrugsSpringer Journals

Published: May 22, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off